Rong's numbers: accelerating progress in HCV therapeutic research.

about

Rong's numbers: accelerating progress in HCV therapeutic research.

Item

http://www.wikidata.org/entity/Q42997306

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Rong's numbers: accelerating progress in HCV therapeutic research.

@en

Rong's numbers: accelerating progress in HCV therapeutic research.

@nl

type

Item

label

Rong's numbers: accelerating progress in HCV therapeutic research.

@en

Rong's numbers: accelerating progress in HCV therapeutic research.

@nl

prefLabel

Rong's numbers: accelerating progress in HCV therapeutic research.

@en

Rong's numbers: accelerating progress in HCV therapeutic research.

@nl

P1476

Rong's numbers: accelerating progress in HCV therapeutic research.

@en

P2093

Robert T Schooley

http://www.w3.org/2001/XMLSchema#string

P2860

Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

P304

33ps25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3001183

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David L Wyles

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20505213

http://www.w3.org/2001/XMLSchema#string